WHO and international epilepsy organisations expose unacceptable state of epilepsy care across Europe
New report provides recommendations to improve the quality of care and understanding of epilepsy, and reduce stigmatisation to help bring epilepsy out of the shadows
[8.00am CET, 26 August, Porto, Portugal] The World Health Organization (WHO) and the two international epilepsy organisations, the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE), have today announced the publication of a report into epilepsy in Europe, which concludes that many aspects of epilepsy care are seriously under-resourced.
The Fostering epilepsy care in Europe report has been developed as part of the IBE/ILAE/WHO Global Campaign Against Epilepsy (GCAE). The report addresses the current challenges faced in epilepsy care and offers recommendations to tackle them, as well as providing a panoramic view of the present epilepsy situation across the continent.
Epilepsy is a highly treatable condition but the existing gaps in epilepsy care and the level of stigmatisation faced by people with epilepsy are simply unacceptable, said Hanneke M. de Boer, Co-ordinator of the Global Campaign Against Epilepsy from the SEIN Epilepsy Institute in the Netherlands. By joining forces to spearhead the GCAE, and by producing and launching this groundbreaking report, WHO, IBE and ILAE are working together to bring epilepsy out of the shadows on behalf of, and with, people with epilepsy in Europe.
Key recommendations for action highlighted in the IBE/ILAE/WHO GCAE European report include:
- Improve access to care for people with epilepsy
- Raise the profile of epilepsy within Europe and work for changes in budgeting and policy-making relating to people with epilepsy
- Develop and implement effective health policy and educational initiatives to reduce the stigma of epilepsy
- Promote and reinforce epilepsy research in the region, including the economic aspects and the more effective use of limited resources
- Make epilepsy surgery, which is potentially curative, more widely available
- Collect information from countries about existing legislation and regulations associated with epilepsy in order to review the comprehensiveness and adequacy of these measures
We are very excited about this report, commented Matt Muijen, Regional Advisor for Mental Health and Brain Disorders of the World Health Organization in the WHO European Region. We believe that the recommendations will help countries to develop activities to combat stigma, restore dignity and reduce the treatment gap for people with epilepsy in Europe. The report is an advocacy tool and an instrument for dialogue with governments, healthcare providers, consumer associations, non-governmental organisations, academic institutions and development partners.
Mortality rates among people with epilepsy are two to three times higher than in the general population, commented Mike Glynn, IBE President. An estimated 40% of all epilepsy-related deaths are as a result of a phenomenon called Sudden Unexpected Death in Epilepsy (SUDEP), yet the mechanism behind SUDEP remains unknown and awareness of risk factors is very low. Research into this and other aspects of epilepsy is vital in order to improve our understanding and ultimately improve patient care.
Epilepsy affects more than six million people in Europe but up to 40% of people with the condition may still be untreated. Epilepsy continues to take its toll, impairing the physical, psychological and social functioning of those affected and causing serious psychological, social and economic consequences for their families. People with epilepsy, and sometimes their family members, are often stigmatised, generating a hidden burden which discourages them from seeking the diagnosis and care they require. Stigma leads to discrimination and it is not uncommon for people with epilepsy to be denied access to education. Discrimination of people with epilepsy in the workplace is also not unusual.
Epilepsy is the clearest example of a neurological disorder for which effective, cost-efficient treatment is available. Recent studies show that, if properly treated, up to 70% of people with this condition could be seizure-free and enjoying a higher quality of life. The need for acceptance and access to treatment is paramount. This report not only identifies the current gaps in epilepsy care but provides cogent recommendations to address these challenges.
Access the report at:
For further information please contact:
Executive Director, IBE
Mobile: +353 86 8914046
Communications Advisor to the IBE President
Mobile: +353 86 8108600
Tel: +44 20 7300 6352
Mobile: +44 7887 85 22 75
Notes to editors:
About the IBE/ILAE/WHO Global Campaign Against Epilepsy
The aim of the IBE/ILAE/WHO GCAE is to assist governments worldwide to ensure that the diagnosis, treatment, prevention and social acceptability of epilepsy are improved. The strategy has two parallel tracks: raising general awareness and understanding of epilepsy; and supporting national Ministries of Health to identify the needs and to promote education, research, training, prevention, treatment and care services.
The campaign has been officially launched, and activities are under way in over 70% of the countries of the European Region. The collaboration between IBE, ILAE and WHO has given the Campaign the opportunity to build a framework for concerted action on global, regional and national levels to raise awareness and diminish the treatment gap.